Clicky

Orgenesis Inc.(ORGS)

Description: Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.


Keywords: Biotechnology Diabetes Stem Cell Cell Therapy Clinical Development Contract Manufacturing Contract Manufacturing Services Regenerative Medicine Insulin Endocrine System Hormones Peptide Hormones Medicinal Products I Diabetes Manufacturing Practice Embryonic Stem Cell Assay Development Services Contract Development And Manufacturing Organization Diabetes Mellitus Type 1 Medicinal Product

Home Page: www.orgenesis.com

ORGS Technical Analysis

20271 Goldenrod Lane
Germantown, MD 20876
United States
Phone: 480 659 6404


Officers

Name Title
Ms. Vered Caplan M.Sc. Chairperson of the Board, CEO & Pres
Mr. Neil T. Reithinger CPA CFO, Sec. & Treasurer
Dr. Efrat Assa Kunik Chief Devel. Officer
Prof. Sarah Ferber Ph.D. Founder & Chief Scientific Officer
Mr. Evan Fishman Chief Financial Officer
Dan Slonim COO & GM of Orgenesis Israel
Dr. Shimon Hassin Ph.D. Chief Technology Officer
Ms. Osher Partok Rheinisch Gen. Counsel & Compliance Officer
Mr. Vincent Vandamme Sr. VP of Quality Strategy

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.6996
Price-to-Sales TTM: 1.779
IPO Date: 2012-03-12
Fiscal Year End: November
Full Time Employees: 151
Back to stocks